PALO ALTO, Calif.--CV Therapeutics and Incyte Pharmaceuticals have entered into a collaboration to develop a prototype gene expression database in the area of cardiovascular biology. The companies said the research program will address some major cardiovascular disease states, such as atherosclerosis and restenosis. Incyte will contribute its genomics capabilities, while CV will provide its molecular cardiology expertise.
Incyte will own the resulting data, and CV will receive a perpetual, nonexclusive license to use the data in its drug development efforts.
"The era of developing drugs by following the biological response of a single gene is drawing to a close," stated Richard Lawn, CV's vice-president of discovery research.